Skip to content

Study · Randomized controlled trial · n = 71 · 2002

4 results

Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.

Sharifi R, Browneller R

The Journal of urology1 Sept 2002Cited by 32 (Europe PMC)

PMID12187208 (opens in a new tab)DOI10.1016/s0022-5347(05)64560-0 (opens in a new tab)PepBankPUB-12187208
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with advanced prostate cancer, monthly and 3-month leuprolide depots produced nearly identical, uniform testosterone suppression throughout dosing intervals.

    In plain wordsIn men with prostate cancer, monthly and 3-month leuprolide depots suppressed testosterone similarly throughout dosing intervals.

    Peptide
    Leuprolide
    Outcome
    No significant changeTestosterone suppression
    Study

    n = 71

    Comparator
    Monthly versus 3-month leuprolide depot
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    7.5 mg monthly or 22.5 mg every 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The 2 formulations produced nearly identical patterns of testosterone suppression which included uniform suppression throughout the duration of the dosing intervals.
    1 context sentence
    Summary · context
    A total of 71 patients were enrolled in a randomized prospective study comparing the pattern of serum testosterone suppression and the potential for agonistic stimulation of serum testosterone following reinjection ("acute-on-chronic" effect) during treatment of advanced stage prostate cancer with m…
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer, neither leuprolide formulation showed a testosterone stimulation pattern after repeat depot injections.

    In plain wordsIn men with prostate cancer, neither leuprolide formulation showed testosterone stimulation after repeat depot injections.

    Peptide
    Leuprolide
    Outcome
    Not applicableAgonistic testosterone stimulation after reinjection
    Study

    n = 71

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    7.5 mg monthly or 22.5 mg every 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Assessment of agonistic stimulation ("acute-on-chronic" response) following the second depot injection as well as the depot injection following 3 months of treatment for each formulation revealed no pattern of stimulation.
    1 context sentence
    Summary · context
    A total of 71 patients were enrolled in a randomized prospective study comparing the pattern of serum testosterone suppression and the potential for agonistic stimulation of serum testosterone following reinjection ("acute-on-chronic" effect) during treatment of advanced stage prostate cancer with m…
  3. 03HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer, one monthly leuprolide recipient had a single testosterone escape above 50 ng./dl.

    In plain wordsIn men with prostate cancer, one monthly leuprolide recipient had a temporary testosterone escape above 50 ng./dl.

    Peptide
    Leuprolide
    Outcome
    Not applicableTransient testosterone escape with monthly depot
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    7.5 mg monthlyAs given in this study (human).

    Measurements

    Patients with escape
    1 patient
    monthly formulation
    Escape threshold
    > 50 ng./dl.
    testosterone

    Source sentences

    Summary
    A transient minor "escape" from suppression (defined as a single testosterone value greater than 50 ng./dl. once suppression was achieved) occurred in 1 patient receiving each formulation.
    1 context sentence
    Summary · context
    A total of 71 patients were enrolled in a randomized prospective study comparing the pattern of serum testosterone suppression and the potential for agonistic stimulation of serum testosterone following reinjection ("acute-on-chronic" effect) during treatment of advanced stage prostate cancer with m…
  4. 04HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer, one 3-month leuprolide recipient had a single testosterone escape above 50 ng./dl.

    In plain wordsIn men with prostate cancer, one 3-month leuprolide recipient had a temporary testosterone escape above 50 ng./dl.

    Peptide
    Leuprolide
    Outcome
    Not applicableTransient testosterone escape with 3-month depot
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    22.5 mg every 3 monthsAs given in this study (human).

    Measurements

    Patients with escape
    1 patient
    3-month formulation
    Escape threshold
    > 50 ng./dl.
    testosterone

    Source sentences

    Summary
    A transient minor "escape" from suppression (defined as a single testosterone value greater than 50 ng./dl. once suppression was achieved) occurred in 1 patient receiving each formulation.
    1 context sentence
    Summary · context
    A total of 71 patients were enrolled in a randomized prospective study comparing the pattern of serum testosterone suppression and the potential for agonistic stimulation of serum testosterone following reinjection ("acute-on-chronic" effect) during treatment of advanced stage prostate cancer with m…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.